{"url_path":"/sec/fbrx/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-224214-index.html","accession_number":"0001193125-26-224214","cik":"0001419041","ticker":"FBRX","issuer_name":"Forte Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-224214-index.html","primary_entity_key":"0001419041","primary_entity_name":"Forte Biosciences, Inc."},"word_count":119,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\nOn May 11, 2026, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}